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Abstract
Adipose-derived mesenchymal stem cells markedly attenuated brain infarct size and improved neurological function in rats. The
mechanisms for neuronal cell death have previously been defined in stress states to suggest that an influx of calcium ions into the
neurons activates calpain cleavage of p35 into p25 forming a hyperactive complex that induces cell death. Nowwe report that p5,
a 24-residue peptide derived from p35, offers protection to neurons and endothelial cells in vitro. In vivo administration of human
adipose-derivedmesenchymal stem cells (hADMSCs) loadedwith this therapeutic peptide to post-stroke rats had no effect on the
infarct volume. Nevertheless, the treatment led to improvement in functional recovery in spatial learning and memory (water
maze), bilateral coordination and sensorimotor function (rotating pole), and asymmetry of forelimb usage (cylinder test).
However, the treatment may not impact on cutaneous sensitivity (adhesive tape removal test). In addition, the double immuno-
fluorescence with human cell-specific antibodies revealed that the number of surviving transplanted cells was higher in the peri-
infarcted area of animals treated with hADMSCs + P5 than that in hADMSC-treated or control animals, concomitant with
reduced number of phagocytic, annexin3-positive cells in the peri-infarcted region. However, the combination therapy did not
increase the vascular density in the peri-infarcted area after stroke. In conclusion, administration of hADMSC-loaded p5 peptide
to post-stroke rats created conditions that supported survival of drug-loaded hADMSCs after cerebral ischemia, suggesting its
therapeutic potential in patients with stroke.
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Introduction
Therapeutic standard procedure for ischemic stroke is cerebral
artery recanalization with tissue-type plasminogen activator
(tPA). However, brain inflammation and comorbidities have
a negative impact on successful revascularization and func-
tional outcome [1–5].
Numerous studies have shown that bone marrow mesen-
chymal stem cell (BMSC) transplantation could foster the
recovery of neurological function and reduce infarct size in
rats with acute ischemic stroke [6, 7]. In the animal model of
cerebral ischemia, BMSC transplantation could improve neu-
rological functional outcomes and decrease the infarction size
via differentiation, replacement, and neural circuit reconstruc-
tion by enhancing angiogenesis [8]. Further, adipose-derived
mesenchymal stem cells markedly attenuated brain infarct size
and improved neurological function in rats [9].
Combinations of MSCs and the peptide granulocyte
colony-stimulating factor (G-CSF), given separately, to post-
stroke aged rats led to a robust and consistent improvement of
neurological function after 28 days [10]. The combination
therapy also led to robust angiogenesis in the formerly infarct
core and in islets of the soft tissue beyond [11].
Cyclin-dependent kinase 5 (CDK5), a serine/threonine ki-
nase, in complex with its activators, p35 (protein of 35 kDa)
and p39 (protein of 39 kDa), is essential for early
neurodevelopment in mammals [12]. However, a variety of
neurotoxic conditions, such as ischemic brain damage, oxida-
tive stress, amyloid-β peptide (Aβ), excitotoxicity, calcium
dyshomeostasis, and inflammation, induce influx of Ca2+ ions
and the rise in the intracellular Ca2+, thereby promoting acti-
vation of calpain, a Ca2+-activated protease, which in turn
cleaves p35 into p25 and a p10 fragment [13, 14]. p25 forms
a more stable CDK5-p25 hyperactive complex, which causes
aberrant hyperphosphorylation of various substrates of CDK5
like tau and neurofilament, that leads to neuronal apoptosis
and is associated with neuropathology. Therefore, a therapeu-
tic approach directed specifically at CDK5-p25 complex
might prove successful. To improve its therapeutic efficacy,
several peptides consisting of amino acid residues of p35,
such as CDK5 inhibitory peptide (CIP, a peptide of 125
amino acid residues), p10, and p5, have been generated
and proven to specifically reduce CDK5-p25 increased ac-
tivity without affecting the normal endogenous CDK5-p35
or other CDK activities [15–21]. In particular, p5 also re-
duced neuronal apoptosis induced by Ca2+ in hypoxia/
ischemia brain injury [22, 23].
Recently, BMSCs have been used as vectors in cancer ther-
apy by delivering oncolytic viruses and drug-loaded nanopar-
ticles [15]. Moreover, a recent study has shown that MSC
given through their natural container (MFAT) led to an im-
proved MSC survival and therefore may prolong the delivery
of the molecule/proteins transported [16]. However, the use of
BMSCs as drug carrier of the CIP peptide for stroke has not
been tested. In this work, we hypothesized that a prolonged
delivery of the CIP peptide by fat-derived MSC may lead to
improved post-stroke recovery by blocking neuronal and en-
dothelial cell apoptosis through CDK5-p35 and subsequent
p53 activation [17]. This pathway was previously shown to
be a key initiator of cellular apoptosis following stroke, asso-
ciated with excitotoxic release of calpains and subsequent
hyper-phosphorylation of the CDK5 protein following p35
conversion to p25 [18, 19].
Methods
Cell Culture
Human adipose-derived mesenchymal stem cells
(hADMSCs) were provided by Professor Giulio Alessandri
and Professor Valentina Ceserani. hADMSCs were isolated
from peri-umbilical fat tissue and characterized as described
[20]. Human neuroblastoma neuroblastic type SH-SY5Y cells
and bovine aortic endothelial cells (BAECs) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Lonza) sup-
plemented with 10% FBS and 1% L-glutamine.
p5 Priming of hADMSCs
p5, a 24-residue peptide, derived from p35, the CDK5 activa-
tor, was chemically synthesized with 5-FAM conjugated on
the N-terminus and KRKR-KRKRwrapper on the C-terminus
[15] (Cambridge Research Biochemicals). The sequence of p5
p e p t i d e i s [ 5 - F A M ] - K E A F - W -
DRCLSVINLMSSKMLQINAKRKRKRKR-amide. The
toxicity of p5 on hADMSCs was determined in a 24-h
alamarBlue assay (cytotoxicity test; Life Technologies) and
in a 3-day alamarBlue assay (anti-proliferative test). Based
on these results, the p5 priming of hADMSCs was carried
out with two concentrations, 25 μg/ml and 100 μg/ml.
In Vitro Proliferation Assay
The protective effect of both p5 or CM of p5 primed
hADMSCs on SH-SY5Y cells and BAEC proliferation after
the treatment of Ca2+ ionophore combined with CaCl2 was
determined by the alamarBlue assay (Life Technologies).
Briefly, 7.0 × 104 SH-SY5Y cells or 1.0 × 103 BAECs were
plated in 96-well multiwell plates in DMEM. The cells were
then treated with 5 μM calcium ionophore A23187 (Sigma-
Aldrich) and 2.5 mM CaCl2 (Sigma-Aldrich) with or without
p5 or CM of p5-primed hADMSCs. Three wells were devoted
for the assay every day for 3 days, and time course of cell
proliferation was monitored.
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Animals and Experimental Design
The subjects of these experiments were male Sprague-Dawley
rats (n = 40; 3–4 months of age) 320–400 g kept under stan-
dard laboratory conditions with free access to food and water.
The numbers reported in the results refer to the number of
animals that survived the surgery and completed the 4-week
testing period. All appropriate measures were taken to mini-
mize pain and suffering.
Randomization
A scientist was in charge of randomization by (i) group as-
signment; (ii) behavioral testing; (iii) surgery assignment; and
(iv) treatment assignment.
Behavioral Testing
To evaluate changes in neurological function associated with
ischemia, the rats were subjected to a variety of somatosenso-
ry, motor, learning, and memory tests before and after surgery.
All testing was performed from 09:00 to 11:00. Results ob-
tained before surgery were used to define 100% functionality
for each animal on each test, and functional recovery was
expressed as percent recovery relative to the pre-surgery
baseline.
Bilateral Sensorimotor Coordination: Rotating
Beam-Walking Test
The rotating pole task assesses coordination and sensorimotor
function in the middle cerebral artery occlusion (MCAO)
model. Each rat was tested for its ability to cross a rotating
(6 rpm) horizontal rod. The score assessment was done as
previously described [10, 21]. Briefly, the time taken for the
rat to traverse the rotating cylinder and join a group of rats
visible at the finish line was measured. The score assessment
was twofold: (i) time (s) required to traverse the rotating cyl-
inder and (ii) the score as follows: 0 = rat falls immediately
(onto a soft surface); 1 = rat does not walk forward, but stays
on the rotarod; 2 = rat walks, but falls before reaching the goal;
3 = rat traverses the rod successfully, but the limbs are used
asymmetrically; 4 = the left hindlimb is used less than 50% of
the time taken to traverse the rod; 5 = the rat successfully
traverses the rod, but with some difficulties; 6 = no mistakes,
symmetric movements.
Asymmetric Sensorimotor Deficit: Adhesive Tape
Removal Test (Tape Test) and Cylinder Test
We assessed the asymmetry of sensorimotor deficit of the
forelimbs induced by unilateral MCAO, by tape test and cyl-
inder test as previously described [10, 21]. For the cylinder
test, the forelimb use asymmetry during vertical exploration of
the walls of a 20-cm-diameter and 40-cm-height glass cylinder
was measured. Rats which did not make at least 20 explorato-
ry contacts with the walls were excluded from the analysis
procedure. The asymmetry index was calculated as (Right −
Left)/(Right + Left), where Right and Left are the number of
contacts of the right.
Spatial Learning and Memory: Morris Water Maze
TheMorris water maze taskwas used to assess spatial learning
and memory. One week before surgery, aged rats were trained
to find a submerged platform in a large (180-cm-diameter)
pool filled to within 20 cm of the upper edge with water
maintained at 26 °C as previously described [10]. The swim
path was recorded by an image analysis system (Noldus,
Holland) that computed path length and percentage of time
spent in each of the four quadrants.
Surgery
Cerebral infarction was induced by transcranial interruption of
blood flow by transiently lifting the middle cerebral artery
(MCA) with a tungsten hook as previously described [19].
Throughout surgery, anesthesia was maintained by spontane-
ous inhalation of 2% isoflurane in a mixture of 70% nitrous
oxide and 30% oxygen. After 90 min, the tungsten hook was
released and the common carotid arteries were re-opened.
Surgery was performed under antiseptic conditions to mini-
mize the risk of infection. The rats then received 0.05 mg/kg
SC buprenorphine (sc) for treatment of post-operative pain.
Subsequent to survival times of 28 days, the rats were
deeply anesthetized and perfused with neutral buffered saline
followed by buffered 4% freshly depolymerized paraformal-
dehyde. The brain was removed, post-fixed in 4% buffered
paraformaldehyde for 24 h, cryoprotected in 15% glycerol
prepared in 10 mM phosphate-buffered saline, flash-frozen
in isopentane, and stored at − 70 °C until sectioning.
Treatments
The contents of the frozen vials containing hADMSCs are re-
suspended in a T75 flask containing 10 ml of stem cell medi-
um (SCM). After a period of about 24 h, the media was re-
moved and replaced with fresh SCM primed with the thera-
peutic peptide p5 at a final concentration of 10μg/ml. After an
incubation period of 24 h, the cells were washed 3 times with
PBS before trypsinization. One group of rats (n = 8) was treat-
ed with 1 × 106 hADMSCs, given intracortically at 3 different
locations in the exposed area proximal to the occluded middle
cerebral artery, immediately after stroke. The second group
(n = 8) was treated with hADMSCs + p5 and the control
(n = 8) group was treated with the vehicle.
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Determination of Infarct Volume
by Immunohistostaining
To assess the size of the infarct induced by focal ischemia, we
used mouse anti-NeuN immunostaining [10]. Every 20th free-
floating section of 25 μm was immunostained for NeuN to
cover the entire infarcted volume, which was then calculated
as the sum of the partial areas using ImageJ.
Collagen IV Immunofluorescence
Sections (25-μm-thick) were cut on a freezing microtome and
processed for immunohistochemistry as previously described
[10]. Briefly, tissue sections were exposed overnight at 4 °C to
rabbit anti-collagen IV (1:2000, Abcam, UK) and the signal
was amplified utilizing an anti-rabbit polymer-based second-
ary detection system (Histofine polymer-HRP, Nichirei,
Japan) diluted 1:10 in PBS containing 1% normal goat serum
and 0.3% Tween 20.
HuNu/CD105 Double Immunofluorescence
For phenotyping, the tissue was incubated with a mix of rabbit
anti-mouse HuNu (1:1000, Novus Biologicals, UK) and
mouse anti-human CD105 (1:1000, antibodies-on-line,
Aachen, Germany) at 4 °C overnight. Next day, sections were
incubated with a mix of Alexa Fluor® 488 goat anti-rabbit
IgG and Alexa Fluor® 555 goat anti-mouse IgG for CD105.
Annexin A3/NeuN/IbaI Triple Immunofluorescence
Cryostat, free-floating sections of 25 μm were fixed in 4%
paraformaldehyde for 15 min and then washed extensively
with PBS and incubated serially with the following primary
antibodies, rabbit anti-AnxA3 (1:500, Abcam, UK), goat anti-
IbaI (1:3000, Abcam, UK), and mouse anti-NeuN (1:1000,
Millipore, Germany). Secondary reagents were donkey anti-
mouse Alexa 488, donkey anti rabbit-Alexa 568, and donkey
anti goat-Alexa 647.
Cell Counting of Co-localized Cells
The number of co-labeled cells (HuNu + CD105-positive) and
(AnxA3/IbaI) cells at the reperfusion times of 28 days was
determined by counting cells on every tenth section in system-
atic random series across the entire infarcted volume as previ-
ously described [10].
Quantitation of Microvascular Density
Microvascular density was quantitated using the “hot spot”
analysis. Briefly, hot spots, i.e., regions with a high density
of collagen IV-positive microvessels, were identified using a
× 40 objective and were then counted using × 20 objective,
corresponding to a microscopic field of 0.7386 mm2 as previ-
ously described [11].
Statistical Analyses
Statistical analysis was performed using SPSS (V 22.0).
Behavioral data were analyzed using two-way ANOVA (treat-
ment × duration) with post-stroke time as a repeated measure-
ment factor. The Greenhouse-Geisser correction was applied
where the sphericity was violated. T tests were performed for
the single parameter comparison, and unequal variance between
groups was assumed. All values are presented as mean ± SEM.
p values < 0.05 were considered statistically significant.
Results
p5-Primed HADMSCs Protected Neurons
and Endothelial Cells from Calpain-Induced Toxicity
As the Ca2+ ionophore and CaCl2 treatment activated apoptosis-
related genes, such as p53 and caspase-3, we have examined the
cytotoxic effects of the combined treatment of Ca2+ ionophore
and CaCl2 on neurons (SH-SY5Y cells) and endothelial cells
(BAECs). Compared to the untreated control cells, the 10-min
treatment with Ca2+ ionophore and CaCl2 caused the immediate
cell death on SH-SY5Y cells on day 1 (Fig. 1). Furthermore, the
Ca2+ ionophore and CaCl2 treatment inhibited BAEC growth
through 3-day culture, resulting in 71.4% reduction on day 3
although the Ca2+ ionophore and CaCl2 treatment did not affect
the SH-SY5Y cell proliferation (Fig. 1).
We then investigated whether p5 or p5-primed hADMSCs
would protect SH-SY5Y and endothelial cells (BAECs)
against the cytotoxicity induced by Ca2+ ionophore and
CaCl2 treatment.
The immediate cytotoxic assay on day 1 and proliferation
assay on the following 2 days showed that neither p5 nor CM
of untreated hADMSCs affected the SH-SY5Y cells or BAEC
numbers with the 10-min treatment of Ca2+ ionophore and
CaCl2, although p5 alone provided the slight protection in
SH-SY5Y cells against immediate cytotoxicity induced by
Ca2+ ionophore and CaCl2 treatment (Fig. 1). However, com-
pared with the treatment of Ca2+ ionophore and CaCl2 alone,
SH-SY5Y cell numbers in CM from 100 μg/ml p5-primed
hADMSCs collected on day 1 and day 2 and CM from
25 μg/ml p5-primed hADMSCs collected on day 1 signifi-
cantly increased by 22.8%, 25.3%, and 25.6%, respectively,
with immediate cytotoxic assay on day 1. Therefore, the CM
of p5-primed hADMSCs provided better protection on neu-
rons than endothelial cells against the immediate cytotoxicity
induced by the calpain activation.
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More encouragingly, the CM from 100 μg/ml p5-primed
hADMSCs completely restored the cell growth in both neu-
rons and endothelial cells after the treatment of Ca2+ iono-
phore and CaCl2 with the similar cell numbers as those in
the untreated control group on day 3.
Behavioral Testing
The experimental design and time flow of treatment and test-
ing are shown in Fig. 2. To facilitate feeding during the first
3 days post-stroke, all animals were fed with moistened, soft
pellets. The mortality rates were almost identical, 14% for
each group. All deaths occurred between day 3 and day 10
post-stroke.
Bilateral Sensorimotor Coordination: Rotating Pole
Test
At baseline, rats traversed the rod within 3 s with no mistakes
(score of 6) and no differences in performance were observed
between rats assigned to control and treatment groups (Fig.
2a). On day 4 following MCAO, for both rotating speeds, the
performance on the rotating beam was impaired in all groups
but both treatment groups showed significant improvement
over the control group (p < 0.05) (Fig. 2a, b). Thereafter, the
rats treated with the combination MSCs + p5 recovered in-
creasingly better, particularly on day 28 (Fig. 2a) as compared
to the control group. However, with increasing difficulty
(6 rpm), the significance of recovery of the bilateral sensori-
motor coordination diminished (Fig. 2b). In addition, no sig-
nificant interaction (treatment × duration) effect was found for
both speeds in the rotating pole test.
Asymmetric Sensorimotor Deficit: Adhesive Tape
Removal Test
The time course of changes in recovery pattern of control ani-
mals, animals treatedwithMSCs alone, and animals treatedwith
MSCs + p5 is shown in Fig. 2c. The score significantly dropped
down from baseline to day 7 and significantly improved on day
21 and day 28 (p < 0.001); however, no significant interaction
(treatment × duration) was found. Though the scores from the
rats treated with the combination of MSCs and p5 were slightly
improved over the other treatment or controls at all time points
after stroke, they were not statistically significant.
Asymmetric Sensorimotor Deficit: Cylinder Test
The forelimb asymmetry index indicated a strong deviation to
the right (ipsilateral to the injured hemisphere) in controls
(0.33 ± 0.04) as compared to MSCs + p5-treated rats (0.25 ±
0.03) on day 7 post-stroke. In addition, both treatment groups
showed significant improvement over the control group on day
28 post-stroke (control versus MSCs, control versus MSCs
together with peptide; both p < 0.01). No significant interaction
effect was found between time and treatment factor (Fig. 2d).
Water Maze Test
The statistical analysis revealed that there was a significant
reduction of treatments on time taken by rats to reach the sub-
merged platform (p = 0.005). No significant effect of the inter-
action (time × treatment) was found, suggesting that the pattern
of recovery related to spatial learning and memory was similar
between different groups at different time points after stroke.
Fig. 1 The conditioned medium (CM) from p5-primed hADMSCs
protected human neurons (SH-SY5Y cells) and endothelial cells
(BAECs) from calpain-induced cytotoxicity. The cultured SH-SY5Y
cells and BAECs were treated with p5 or CM from 100 μg/ml or
25 μg/ml p5-primed hADMSCs collected on day 1 and day 2 for 1 h,
then further treated with 5 μM calcium ionophore A23187 and 2.5 mM
CaCl2 for 10 min. The cell proliferation was monitored for 3 consecutive
days using the alamarBlue assay. Data are means ± SD (error bars).
Significance (denoted as an asterisk) was calculated compared to the
control using one-way ANOVAwith Bonferroni post-test analysis (with
*p < 0.05; **p < 0.01, = 3)
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The Effect of Cell Therapy on the Infarct Volume
Immunohistochemical staining of the infarct area on day 28
using an anti-NeuN antibody showed that the infarcted corti-
cal volumes were largely similar and independent of treatment
as compared to controls (Fig. 3). The anti-NeuN antibody
sharply delineated the infarcted area.
The Survival Rate of Transplanted Cells Was Higher
in Animals Treated with hADMSCs + p5
In the ipsilateral hemisphere, the injected human hADMSCs
were detected in the perilesional area by double immunofluo-
rescence with anti-human specific antibodies, HuNu (nuclear,
green) and CD105 (cytoplasmic, red) (Fig. 4). We noted that
in the peri-infarcted area of animals treated with hADMSCs +
p5 (Fig. 4b, arrows), the number of surviving transplanted
cells was 2.5-fold higher (Fig. 4c) than in hADMSC-treated
animals (Fig. 4a).
hADMSCs Loaded with p5 Reduced the Number
of Inflammatory Cells in the Peri-infarcted Area
Cell survival in the perilesional area after stroke is limited by
an exaggerated inflammatory response. We asked if the neu-
roprotective effect of hADMSCs loaded with p5 might be a
consequence of decreased number of inflammatory cells in the
perilesional area. Indeed, by triple immunofluorescence phe-
notyping and cell counting, we found that the number of
AnxA3/IbaI co-localized cells was decreased by 35% in
Fig. 2 Experimental design
(upper panel) and time course of
behavioral recovery after
treatment with mesenchymal cells
and p5. a, b Functional recovery
on a rotating pole at 3 and 6 rpm.
c, d Time course of changes in
sensorimotor function recovery
after stroke therapy according to
adhesive tape removal and
cylinder test. Asymmetry of
forelimb usage for the postural
weight support in rats after stroke
therapy. e Time course of post-
stroke recovery of (spatial)
learning and memory by using
water maze test. Significance be-
tween groups is denoted as
*p < 0.05; **p < 0.01, compared
to the control group. “a”,
significantly different from
baseline
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Fig. 4 The survival rate of
transplanted cells was higher in
animals treated with hADMSCs +
p5. Note that in the peri-infarcted
area of animals treated with
hADMSCs + p5 (b, arrows), the
number of surviving transplanted
cells was 2.5-fold higher (d) than
in hADMSC-treated (a) animals.
The nuclei in the peri-infarcted
area of vehicle-treated animals is
shown in c (***p = 0.001)
Fig. 3 Stroke volumes by NeuN
immunohistochemistry. By
immunohistochemistry at day 28,
the infarct volumes for controls
(a), MSCs alone (b), and MSCs +
p5 (c) were largely similar (e).
NeuN immunohistochemistry
sharply delineated the infarcted
area (d). Cc corpus callosum, Cx
cortex, IC infarct core
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animals treated with hADMSCs + p5 (Fig. 5d). Occasionally,
we found that microglial cells that were immunopositive for
both IbaI and ANXA3 wrapped around neurons, highly sug-
gesting an association of ANXA3 expression with a phago-
cytic phenotype (Fig. 5a–c).
hADMSCs Loaded with p5 Did Not Increase Vascular
Density in the Peri-infarcted Area
Treatment with MSCs stimulates post-stroke angiogenesis [4,
8]. We asked if the neuroprotective effect of hADMSCs load-
ed with p5 might be a consequence of increased vascularity in
the perilesional cortex. We found that the treatment with
hADMSCs alone led to a significant increase (2.1-fold) in
the vascular density in the peri-infarcted area as compared to
control animals (Fig. 6a). Although the treatment of animals
with hADMSCs + p5 (Fig. 6b) did also increase (2.3-fold) the
vascular density in the peri-infarcted area, the increase was not
significant (Fig. 6c, d).
Discussion
In ischemic stroke, the mechanisms for neuronal cell death has
previously been defined in stress states to suggest that an
influx of calcium ions into the neurons activates calpain cleav-
age of p35 into p25 forming a hyperactive complex that in-
duces cell death. Now we report that p5 offers protection to
both SH-SY5Y and BAEC cells. In vivo administration of
hADMSCs loaded with the therapeutic peptide p5 to post-
stroke rats led to improvement in functional recovery and
increased number of surviving transplanted cells, most likely
by reducing the number of inflammatory ANXA3/IbaI-
positive cells in the peri-infarcted region.
Previous work has identified that p5 offers protection to
both neurons and endothelial cells [12, 20]. Indeed, this pres-
ent study has demonstrated a specific protection towards neu-
rons in vitro. We found that p5 offers protection to SH-SY5Y
and BAEC cells, although the protection for SH-SY5Y cells
was much more significant when compared to the control.
Specifically, the data showed p5 protection for SH-SY5Y cells
throughout the 3 days in all conditions, peaking on day 2, with
continual significance to both control groups. This significant
finding indicates the high affinity neurons have for p5. When
comparing the protection of BAECs at no time point did p5
offer protection greater than the control group, and similarly to
SY5Y cells, protection increased over time until day 2 when
p5 25DRD1 and 25DRD2 displayed negative values of cell
number. This infers that p5 at that concentration within the
endothelial cell inhibited CDK5-p35 rather that CDK5-p25,
suggesting that higher dosages are required for BAEC
protection.
Surprisingly, the CM from p5-primed hADMSCs provided
much stronger protection than p5 alone and CM of untreated
hADMSCs did not show any protection against the calpain
activation induced by the treatment of Ca2+ ionophore and
CaCl2. These findings suggest that hADMSCs might release
other trophic factors, which could work together with released
p5 in the CM, thereby providing more potent therapeutic
effects.
Fig. 5 AnnexinA3/NeuN/IbaI
triple immunofluorescence
phenotyping and cell counting. In
animals treated with hADMSCs +
p5, the number of co-localized
ANXA3/IbaI cells (arrowheads)
was decreased by 35% (d).
Occasionally, microglial cells that
are immunopositive for both IbaI
and ANXA3 wrapped around
neurons (arrows), suggesting an
association of ANXA3
expression with a phagocytic
phenotype (a–c) (**p = 0.01)
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By immunostaining of the infarct area, the infarcted corti-
cal volumes were largely similar on day 28, suggesting that
the treatment with hADMSCs + p5 was not efficacious in
reducing infarct volume. However, in the peri-infarcted area
of animals treated with hADMSCs + p5, the number of sur-
viving transplanted cells was higher than in hADMSC-treated
or control animals, suggesting primarily that the p5 peptide
created conditions that supported survival of drug-loaded
hADMSCs.
The underlying mechanisms could be three-fold. For one,
the therapeutic peptide p5 could block neuronal cell apoptosis
through CDK5-p35 and subsequent p53 activation [12]. In
addition, the hADMSCs + p5 combination may act by reduc-
ing the number of phagocytic ANXA3/IbaI-positive cells in
the peri-infarcted region. Indeed, in previous work on exper-
imental stroke, we identified ANXA3 as a novel marker of
phagocytic microglia after cerebral ischemia [24]. Therefore,
we think that the therapeutic potential of p5 loading of MSCs
in the clinic may be exploited in the first week post-stroke
when neuroinflammation develops at its maximum and may
lead to neuronal death by secondary phagocytosis.
Whenmigratingmicroglia detect the “eat-me” signals, com-
plete or partial and engulfment of these follows. This process
has been coined primary phagocytosis or “phagoptosis” [25,
26]. Further, toxic neuronal insults, such as dying neurons after
stroke, may cause an irreversibly exposure of the “eat-me”
signal by neurons resulting in phagocytosis of dead neurons
or the so-called secondary phagocytosis [27]. It is therefore a
challenge to develop stroke therapies that modulate the capa-
bility of microglia to phagocytose still viable cells in the in-
jured area after cerebral ischemia [28].
Other supportive mechanisms include stroke-stimulated in-
crease in vascular density after stroke in rats [11]. Using an
anti-collagen IV-specific marker, we found that treatment with
the hADMSCs is also effective in enhancing the vascular den-
sity in the formerly infarcted area of rats during the recovery
phase after stroke. However, the hADMSCs + p5 combination
did not further increase the post-stroke vascular density and
therefore it is unlikely that its beneficial effects on transplanted
cell survival in the peri-infarcted area were due the P5 peptide.
In conclusion, administration of human adipose-derived
mesenchymal stem cells (hADMSCs) loaded with the thera-
peutic peptide p5 to post-stroke rats led to improvement in
functional recovery and created conditions that supported sur-
vival of adipose-derived, drug-loaded MSCs after cerebral
ischemia, suggesting its therapeutic potential in patients with
stroke and other CNS disorders [28, 29]. In addition, the dou-
ble immunofluorescence with human cell-specific antibodies
revealed that the number of surviving transplanted cells was
higher in the peri-infarcted area of animals treated with
hADMSCs + p5 than that in hADMSC-treated or control an-
imals, concomitant with reduced number of phagocytic
Fig. 6 Effect of treatment on
post-stroke vascular density.
Treatment with hADMSCs alone
(b) or with hADMSCs + p5 (c)
led to a significant increase (2.1–
2.3-fold) in the vascular density in
the peri-infarcted area as com-
pared to control animals (a)
(***p = 0.001)
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ANXA3/IbaI-positive cells in the peri-infarcted region.
However, the mechanisms underlying the beneficial effects
of the hADMSCs + p5 combination may not be simple and
shall be investigated in a multidisciplinary study. In particular,
it is not known whether hADMSCs process p5 into smaller
neuroprotective peptides or p5 treatment causes hADMSCs to
release neuroprotective factors.
Funding Information This study was funded by UEFISCDI, research
grant PN-II-ID-PCE-2012-4-0133 to MS; project numbers PN-III-P4-
ID-PCE-2016-0340 to DH; and PN-III-P4-ID-PCE-2016-0215 to
APW]. This work was also partially funded by the European
Commission through Move-Age, an Erasmus Mundus Joint Doctorate
Program (2011–0015).
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflict of
interest.
Ethical Approval All studies with use of laboratory animals were being
performed in accordance with Directive 2010/63/EU of the European
Parliament and The Council of 22 September 2010 on the protection of
animals used for scientific purposes with relevant Acts and Regulations.
All protocols were approved by the local animal ethics committee, 89-
12102017. This article does not contain any studies with human partici-
pants performed by any of the authors.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate if
changes weremade. The images or other third party material in this article
are included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Griemert EV, Recarte Pelz K, Engelhard K, Schäfer MK, Thal SC.
PAI-1 but not PAI-2 gene deficiency attenuates ischemic brain in-
jury after experimental stroke. Transl Stroke Res. 2019;10(4):372–
80. https://doi.org/10.1007/s12975-018-0644-9.
2. Navarro-Oviedo M, Roncal C, Salicio A, Belzunce M, Rabal O,
Toledo E, et al. MMP10 promotes efficient thrombolysis after is-
chemic stroke in mice with induced diabetes. Transl Stroke Res.
2019;10(4):389–401. https://doi.org/10.1007/s12975-018-0652-9.
3. Liu L, Yuan H, Yi Y, Koellhoffer EC, Munshi Y, Bu F, et al. Ras-
related C3 botulinum toxin substrate 1 promotes axonal regenera-
tion after stroke in mice. Transl Stroke Res. 2018;9(5):506–14.
https://doi.org/10.1007/s12975-018-0611-5.
4. Kim E, Yang J, Park KW, Cho S. Inhibition of VEGF signaling
reduces diabetes-exacerbated brain swelling, but not infarct size, in
large cerebral infarction in mice. Transl Stroke Res. 2018;9(5):540–
8. https://doi.org/10.1007/s12975-017-0601-z.
5. Blecharz-Lang KG,Wagner J, Fries A, Nieminen-Kelhä M, Rösner
J, Schneider UC, et al. Interleukin 6-mediated endothelial barrier
disturbances can be attenuated by blockade of the IL6 receptor
expressed in brain microvascular endothelial cells. Transl Stroke
Res. 2018;9(6):631–42. https://doi.org/10.1007/s12975-018-0614-
2.
6. Chen JR, Cheng GY, Sheu CC, et al. Transplanted bone marrow
stromal cells migrate, differentiate and improve motor function in
rats with experimentally induced cerebral stroke. J Anat. 2008.
https://doi.org/10.1111/j.1469-7580.2008.00948.x.
7. Shichinohe H, Ishihara T, Takahashi K, Tanaka Y, Miyamoto M,
Yamauchi T, et al. Bonemarrow stromal cells rescue ischemic brain
by trophic effects and phenotypic change toward neural cells.
Neurorehabil Neural Repair. 2015;29(1):80–9. https://doi.org/10.
1177/1545968314525856.
8. Deng YB, Ye WB, Hu ZZ, et al. Intravenously administered
BMSCs reduce neuronal apoptosis and promote neuronal prolifer-
ation through the release of VEGF after stroke in rats. Neurol Res.
2010. https://doi.org/10.1179/174313209X414434.
9. Leu S, Lin YC, Yuen CM, et al. Adipose-derived mesenchymal
stem cells markedly attenuate brain infarct size and improve neuro-
logical function in rats. J TranslMed. 2010. https://doi.org/10.1186/
1479-5876-8-63.
10. Balseanu AT, Buga AM, Catalin B, et al. Multimodal approaches
for regenerative stroke therapies: combination of granulocyte
colony-stimulating factor with bone marrow mesenchymal stem
cells is not superior to G-CSF alone. Front Aging Neurosci. 2014.
https://doi.org/10.3389/fnagi.2014.00130.
11. Buga AM, Margaritescu C, Scholz CJ, et al. Transcriptomics of
post-stroke angiogenesis in the aged brain. Front Aging Neurosci.
2014. https://doi.org/10.3389/fnagi.2014.00044.
12. Slevin M, Krupinski J. Cyclin-dependent kinase-5 targeting for
ischaemic stroke. Curr Opin Pharmacol. 2009. https://doi.org/10.
1016/j.coph.2008.10.003.
13. Lee MS, Kwon YT, Li M, et al. Neurotoxicity induces cleavage of
p35 to p25 by calpain. Nature. 2000. https://doi.org/10.1038/
35012636.
14. Zhang L, Liu W, Szumlinski KK, Lew J. p10, the N-terminal do-
main of p35, protects against CDK5/p25-induced neurotoxicity.
Proc Natl Acad Sci U S A. 2012. https://doi.org/10.1073/pnas.
1212914109.
15. Li Z, Fan D, Xiong D. Mesenchymal stem cells as delivery vectors
for anti-tumor therapy. Stem Cell Investig. 2015;10(39782015).
16. Nava S, Sordi V, Pascucci L, et al. Long-lasting anti-inflammatory
activity of human microfragmented adipose tissue. Stem Cells Int.
2019. https://doi.org/10.1155/2019/5901479.eCollection2019.
17. Lee J-H, Kim H-S, Lee S-J, Kim K-T. Stabilization and activation
of p53 induced by Cdk5 contributes to neuronal cell death. J Cell
Sci. 2007. https://doi.org/10.1242/jcs.03468.
18. Iyirhiaro GO, Im DS, Boonying W, et al. Cdc25A is a critical
mediator of ischemic neuronal death in vitro and in vivo. J
Neurosci. 2017. https://doi.org/10.1523/JNEUROSCI.3017-16.
2017.
19. Pacioni S, D’Alessandris QG, Giannetti S, Morgante L, de Pascalis
I, Coccè V, et al. Mesenchymal stromal cells loaded with paclitaxel
induce cytotoxic damage in glioblastoma brain xenografts. Stem
Cell Res Ther. 2015;6:1–11. https://doi.org/10.1186/s13287-015-
0185-z.
20. Fang W-H, Kumar S, McDowell G, et al. Mesenchymal stem cells
loaded with p5, derived from CDK5 activator p35, inhibit calcium-
induced CDK5 activation in endothelial cells. Stem Cells Int. 2016.
https://doi.org/10.1155/2016/2165462.
21. Popa-Wagner A, Stöcker K, Balseanu AT, et al. Effects of
granulocyte-colony stimulating factor after stroke in aged rats.
Stroke. 2010. https://doi.org/10.1161/STROKEAHA.109.575621.
Transl. Stroke Res.
22. Binukumar BK, ZhengYL, Shukla V, et al. TFP5, a peptide derived
from p35, a Cdk5 neuronal activator, rescues cortical neurons from
glucose toxicity. J Alzheimers Dis. 2014. https://doi.org/10.3233/
JAD-131784.
23. Zheng YL, Amin ND, Hu YF, et al. A 24-residue peptide (p5),
derived from p35, the Cdk5 neuronal activator, specifically inhibits
Cdk5-p25 hyperactivity and tau hyperphosphorylation. J Biol
Chem. 2010. https://doi.org/10.1074/jbc.M110.134643.
24. Junker H, SuofuY, Venz S, SascauM, Herndon JG, Kessler C, et al.
Proteomic identification of an upregulated isoform of annexin A3 in
the rat brain following reversible cerebral ischemia. Glia. 2007;55:
1630–7.
25. FuhrmannM, Bittner T, Jung CKE, et al. Microglial Cx3cr1 knock-
out prevents neuron loss in a mouse model of Alzheimer’s disease.
Nat Neurosci. 2010. https://doi.org/10.1002/glia.20581.
26. Neher JJ, Neniskyte U, Zhao J-W, et al. Inhibition of microglial
phagocytosis is sufficient to prevent inflammatory neuronal death.
J Immunol. 2011. https://doi.org/10.4049/jimmunol.1003600.
27. Brown GC, Neher JJ. Microglial phagocytosis of live neurons. Nat
Rev Neurosci. 2014. https://doi.org/10.1038/nrn3710.
28. Stonesifer C, Corey S, Ghanekar S, et al. Stem cell therapy for
abrogating stroke-induced neuroinflammation and relevant second-
ary cell death mechanisms. Prog Neurobiol. 2017. https://doi.org/
10.1016/j.pneurobio.2017.07.004.
29. Lee J-Y, Lin R, Nguyen H, Grant Liska M, Lippert T, Kaneko Y,
et al. Histopathological and behavioral assessments of aging effects
on stem cell transplants in an experimental traumatic brain injury.
Methods Mol Biol. 2019. https://doi.org/10.1007/7651_2018_121.
Publisher’s Note Springer Nature remains neutral with regard to juris-
dictional claims in published maps and institutional affiliations.
Transl. Stroke Res.
